Literature DB >> 1516184

Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings.

L Fananapazir1, A C Chang, S E Epstein, D McAreavey.   

Abstract

BACKGROUND: Patients with hypertrophic cardiomyopathy (HCM) frequently have arrhythmias and hemodynamic abnormalities and are prone to sudden death and syncope. An important need exists for improved risk stratification and definition of appropriate investigation and therapy. METHODS AND
RESULTS: The relation of 31 clinical, Holter, cardiac catheterization, and electrophysiological (EP) variables to subsequent cardiac events in 230 HCM patients was examined by multivariate analysis. Studies were for cardiac arrest (n = 32), syncope (n = 80), presyncope (n = 52), ventricular tachycardia (VT) on Holter (n = 36), a strong family history of sudden death (n = 9), and palpitations (n = 21). Nonsustained VT on Holter was present in 115 patients (50%). Sustained ventricular arrhythmia was induced in 82 patients (36%). Seventeen cardiac events (eight sudden deaths, one cardiac arrest, and eight syncope with defibrillator discharges) occurred during a follow-up of 28 +/- 19 months. The 1-year and 5-year event-free rates were 99% and 79%, respectively. Two variables were significant independent predictors of subsequent events: sustained ventricular arrhythmia induced at EP study (beta, 3.5; p = 0.002) and a history of cardiac arrest or syncope (beta, 2.9; p less than 0.05). Only two of 66 patients without symptoms of impaired consciousness had a cardiac event (3-year event-free rate, 97%). In contrast, nonsustained VT on Holter was associated with a worse prognosis only in patients with symptoms of impaired consciousness: 11 of 79 symptomatic patients with VT on Holter (14%) had events versus only four of 85 symptomatic patients without VT on Holter (5%) (p = 0.057). Notably, none of 51 patients without symptoms of impaired consciousness in whom VT was not induced at EP study had a cardiac event.
CONCLUSIONS: In HCM, VT on Holter is of benign prognostic significance in the absence of symptoms of impaired consciousness and inducible VT, and sustained VT induced at EP study, especially when associated with cardiac arrest or syncope, identifies a subgroup at high risk for subsequent cardiac events.

Entities:  

Mesh:

Year:  1992        PMID: 1516184     DOI: 10.1161/01.cir.86.3.730

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  34 in total

Review 1.  Patients with ventricular arrhythmias: who should be referred to an electrophysiologist?

Authors:  John M Morgan
Journal:  Heart       Date:  2002-11       Impact factor: 5.994

2.  Symptomatic Ventricular Tachycardia.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-08

3.  On predictors of sudden cardiac death in hypertrophic cardiomyopathy.

Authors:  Ali J Marian
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

Review 4.  Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy.

Authors:  Michael P Frenneaux
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

Review 5.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

6.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Saenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  J Interv Card Electrophysiol       Date:  2020-10       Impact factor: 1.900

Review 7.  [Long term electrocardiography (Holter monitoring)].

Authors:  Axel Brandes; Klaus-Peter Bethge
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2008-10-25

Review 8.  Molecular basis of hypertrophic and dilated cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  Tex Heart Inst J       Date:  1994

9.  Prognosis of hypertrophic cardiomyopathy: assessment by 123I-BMIPP (beta-methyl-p-(123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography.

Authors:  T Nishimura; S Nagata; T Uehara; T Morozumi; Y Ishida; T Nakata; O Iimura; C Kurata; Y Wakabayashi; H Sugihara; K Otsuki; T Wada; Y Koga
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

10.  Missense mutations in the beta-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy.

Authors:  L Fananapazir; M C Dalakas; F Cyran; G Cohn; N D Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.